Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Sanofi-Aventis Licenses Anti-Angiogenesis Technology from SIBS

publication date: Dec 6, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Sanofi-Aventis has in-licensed a technology patent from Shanghai Institutes for Biological Sciences (SIBS) that may lead to an anti-angiogenesis cancer drug. The patent covers SIBS’s discovery of the importance of the Slit-Robo signaling path for tumor vasculature and tumor growth. The total deal is worth $60 million, according to Data Monitor, which includes an upfront payment, milestones and royalties on sales. More details....

Stock Symbol: (NYSE: SNY)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China

>>More events...
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners